Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Allena Pharmaceuticals	Genetic Technologies	Brickell Biotech	Microbot Medical	PharmaCyte Biotech
Symbol	NASDAQ:ALNA	NASDAQ:GENE	NASDAQ:BBI	NASDAQ:MBOT	OTCMKTS:PMCB
Price Information
Current Price	$1.12	$3.87	$0.84	$7.55	$0.02
52 Week Range	Buy	N/A	Buy	Buy	N/A
MarketRank™
Overall Score	1.3	0.4	1.5	1.3	0.5
Analysis Score	3.4	0.0	3.5	3.5	0.0
Community Score	2.6	1.9	1.3	2.8	2.4
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.0	1.7	0.0	0.0
Earnings & Valuation Score	0.6	0.0	1.3	0.0	0.0
Analyst Ratings
Consensus Recommendation	Buy	N/A	Buy	Buy	N/A
Consensus Price Target	$10.40	N/A	$5.50	$20.00	N/A
% Upside from Price Target	828.57% upside	N/A	551.58% upside	164.90% upside	N/A
Trade Information
Market Cap	$63.77 million	$58.16 million	$56.50 million	$53.67 million	$39.36 million
Beta	2.39	2.65	0.34	3.98	0.49
Average Volume	2,083,010	1,985,058	3,556,001	162,593	16,414,969
Sales & Book Value
Annual Revenue	N/A	$10,000.00	$7.92 million	N/A	N/A
Price / Sales	N/A	5,815.84	7.13	N/A	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$0.73 per share	$0.65 per share	$0.97 per share	$5.02 per share	N/A
Price / Book	N/A	5.95	0.87	N/A	N/A
Profitability
Net Income	$-47,340,000.00	$-4,090,000.00	$-23,880,000.00	$-7,250,000.00	$-3,830,000.00
EPS	($2.10)	N/A	($5.11)	N/A	N/A
Trailing P/E Ratio	N/A	0.00	N/A	0.00	0.00
Forward P/E Ratio	N/A	∞	N/A	N/A	∞
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	-990.67%	N/A	N/A
Return on Equity (ROE)	-207.07%	N/A	-187.45%	-28.95%	-57.82%
Return on Assets (ROA)	-112.21%	N/A	-114.85%	-26.60%	-49.63%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.54%	0.02%	N/A	N/A	N/A
Current Ratio	7.99%	10.88%	3.50%	29.32%	5.92%
Quick Ratio	7.99%	10.81%	3.50%	29.32%	5.92%
Ownership Information
Institutional Ownership Percentage	28.03%	1.39%	5.93%	9.47%	0.02%
Insider Ownership Percentage	22.80%	N/A	10.30%	8.69%	N/A
Miscellaneous
Employees	41	N/A	13	10	4
Shares Outstanding	56.94 million	15.03 million	66.93 million	7.11 million	2.39 billion
Next Earnings Date	5/12/2021 (Estimated)	N/A	5/12/2021 (Estimated)	5/21/2021 (Estimated)	8/12/2021 (Estimated)
Optionable	Not Optionable	Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	PharmaCyte Biotech Successfully Completes 1 Year Stability Study finance.yahoo.com - April 1 at 10:06 AM
	PharmaCyte Biotech, Inc. (OTCMKTS:PMCB) Short Interest Update americanbankingnews.com - March 27 at 5:46 PM
	PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for its Clinical Trial Product finance.yahoo.com - January 26 at 1:20 PM
	PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for its Clinical Trial Product finance.yahoo.com - December 14 at 10:43 AM
	PharmaCyte Biotech Successfully Completes 9-Month Stability Study finance.yahoo.com - December 2 at 6:28 PM
	FDA places hold on PharmaCyte's cell therapy IND for pancreatic cancer seekingalpha.com - October 2 at 1:07 PM
	PharmaCyte Biotech’s Investigational New Drug Application Placed on Hold by the U.S. FDA news.yahoo.com - October 2 at 1:07 PM
	PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Period finance.yahoo.com - September 23 at 9:18 AM
	PharmaCyte Biotech Successfully Completes Six-Month Stability Study finance.yahoo.com - September 14 at 1:21 PM
	PharmaCyte Biotech completes second container closure integrity test for CypCaps product pharmabiz.com - September 10 at 10:09 AM
	PharmaCyte Biotech Successfully Completes Second Container Closure Integrity Test finance.yahoo.com - September 8 at 9:12 AM
	PharmaCyte Biotech submits IND to FDA for clinical trial in inoperable pancreatic cancer pharmaceutical-business-review.com - September 3 at 10:23 AM
	PharmaCyte Biotech Announces IND Submitted to U.S. FDA for Clinical Trial in Locally Advanced, Inoperable Pancreatic Cancer finance.yahoo.com - September 2 at 8:56 AM
	PharmaCyte Biotech Appoints Dr. JoséIglesias as Consulting Chief Medical Officer for Clinical Trial in Pancreatic Cancer marketwatch.com - August 10 at 9:57 AM
	PharmaCyte Biotech Appoints Dr. José Iglesias as Consulting Chief Medical Officer for Clinical Trial in Pancreatic Cancer finance.yahoo.com - August 10 at 9:57 AM
	FDA Formally Accepts PharmaCyte Biotech’s Drug Master File for Company’s Pancreatic Cancer Therapy finance.yahoo.com - August 5 at 10:44 AM
	PharmaCyte Biotech Ready to Submit Investigational New Drug Application to FDA for Clinical Trial in Pancreatic Cancer finance.yahoo.com - August 3 at 12:50 PM
	PharmaCyte Biotech Receives CE Mark for Licensed COVID-19 Molecular Tests finance.yahoo.com - July 29 at 9:37 AM
	PharmaCyte Biotech Announces Submission of Drug Master File to FDA for Company’s Pancreatic Cancer Therapy finance.yahoo.com - July 27 at 1:07 PM
	PharmaCyte Biotech Successfully Completes Container Closure Integrity Test finance.yahoo.com - July 13 at 10:30 AM
	PharmaCyte Biotech Successfully Completes Three-Month Stability Study finance.yahoo.com - July 8 at 8:22 AM
	PharmaCyte Biotech's COVID-19 Test Offers "Pool Testing" Dr. Fauci and White House Coronavirus Task Force Now Considering www.benzinga.com - June 29 at 1:42 PM
	PharmaCyte Biotech’s COVID-19 Test Offers “Pool Testing” Dr. Fauci and White House Coronavirus Task Force Now Considering finance.yahoo.com - June 29 at 8:42 AM
	PharmaCyte Biotech Provides IND Submission Update for Pancreatic Cancer Clinical Trial finance.yahoo.com - June 23 at 8:54 AM
	PharmaCyte Biotech Successfully Accelerates Development of Container Closure Integrity Test for Pancreatic Cancer Clinical Trial Product finance.yahoo.com - June 15 at 8:16 AM

Date	Company	Brokerage	Action
10/1/2020	Allena Pharmaceuticals	B. Riley	Boost Price Target
9/10/2020	Allena Pharmaceuticals	Wedbush	Reiterated Rating
9/10/2020	Allena Pharmaceuticals	HC Wainwright	Reiterated Rating
7/15/2020	Allena Pharmaceuticals	Roth Capital	Reiterated Rating
7/15/2020	Allena Pharmaceuticals	LADENBURG THALM/SH SH	Reiterated Rating
2/17/2020	Allena Pharmaceuticals	Credit Suisse Group	Reiterated Rating
11/14/2019	Allena Pharmaceuticals	Cowen	Reiterated Rating
8/28/2020	Brickell Biotech	Lake Street Capital	Initiated Coverage
8/25/2020	Brickell Biotech	Oppenheimer	Initiated Coverage

(Data available from 4/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources